Optimising Cell Line Development for Bioprocessing

  • Sami Ullah, PhD

    Scientist - Tumor Biology, Department for Human and Animal Cell Lines, Leibniz Institute DSMZ (German Collection of microorganisms and cell cultures)


In the last decades, the upstream processing in biopharma industry has been revolutionized regarding the production of bioactive materials such as monoclonal antibodies, proteins and biotherapeutics. More and more cell lines are produced with an aim to increase the productivity and quality of biologics produced. For instance, the mammalian cell lines have gained extreme importance in production of recombinant proteins for different applications. This is in general because of the fact that mammalian cell lines allow proper protein folding and post-translational modification. Although, the process itself starts with introduction of a “gene of interest” in to the cell line, there are a number of factors which needs to be taken in to account before claiming the cell line for biologics production. 

The key factors which drive this process are selection of a suitable cell type, stable cell line development, cell culture media optimization and bioreactor control strategies. 

This talk will focus on the current strategies in stable cell lines development, selection of suitable media for biologics production from cell lines and the current advances in the field of upstream bioprocessing using cell lines. 

Learning objectives:

1. Explain how cell lines are produced and selected for biologics production.

2. Discuss what critical role the media for cell cultivation play in upstream processing.

3. Discuss what the new technologies are that can better the quality of bioprocessing as well as shorten the time for cell lines development.

You May Also Like
Loading Comments...